STOCK TITAN

Know Labs - KNW STOCK NEWS

Welcome to our dedicated page for Know Labs news (Ticker: KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.

Overview

Know Labs Inc is a cutting-edge medical diagnostic company that specializes in the development of non-invasive testing technologies using proprietary Bio-RFID and ChromaID systems. These technologies leverage electromagnetic energy to capture the unique signature of substances, enabling the detection and identification of biomarkers without the need for conventional invasive procedures. By driving innovation in the field of healthcare diagnostics, Know Labs is committed to providing alternatives that enhance patient experience and streamline clinical operations.

Core Technologies and Innovations

Know Labs Inc has developed two main technologies that define its product offerings:

  • Bio-RFID Technology: This technology uses electromagnetic signals to record distinct bio-signatures from various substances, allowing for accurate identification and authentication. It offers a non-invasive approach, minimizing discomfort while delivering precise diagnostic information.
  • ChromaID Technology: Utilizing advanced spectral analysis, ChromaID captures the chromatic signature of materials, facilitating their detection and verification in a manner that bypasses traditional, more invasive methods.

These innovations not only represent significant advancements in diagnostic testing but also hold the potential to redefine standard practices within the medical field.

Applications in Medical Diagnostics

The technologies developed by Know Labs Inc are applicable to a wide range of diagnostic scenarios. A primary focus is on the development of wearable devices that integrate these technologies, such as non-invasive blood glucose monitors. This approach aims to eliminate the need for traditional fingerstick testing, thereby reducing patient discomfort and improving adherence to monitoring regimens. The practical applications of such tools extend beyond diabetes management to potentially encompass a variety of diagnostic uses where traditional methods are cumbersome or invasive.

Market Position and Industry Context

Operating in the competitive healthcare technology and medical diagnostics sector, Know Labs Inc carves out its niche by offering significantly disruptive non-invasive testing methods. Its emphasis on using electromagnetic energy to capture biomolecular signatures sets the company apart from traditional lab-based diagnostic systems. In doing so, Know Labs not only addresses critical challenges such as patient discomfort and procedural inefficiencies but also reinforces its position as a specialist in innovative diagnostic solutions within a rapidly evolving market.

Business Model and Revenue Considerations

The company’s business model centers on the research, development, and commercialization of its proprietary diagnostic technologies. Revenue generation is primarily achieved through the sales and marketing of medical devices and integrated diagnostic systems, along with potential licensing of its technologies to strategic partners. This model allows Know Labs Inc to expand the reach of its innovations throughout various segments of the healthcare industry, further solidifying its role as a transformative force in diagnostics.

Competitive Advantages and Industry Impact

Know Labs Inc distinguishes itself through its commitment to non-invasive, patient-friendly diagnostics. The use of sophisticated electromagnetic energy-based techniques provides an alternative to traditional, often cumbersome laboratory tests. This focus on innovation not only improves the accuracy and speed of diagnosis but also positions the company as a thought leader in the development of next-generation medical devices. The combination of its unique technologies and a strategically diversified product portfolio has the potential to influence the broader healthcare landscape significantly.

Detailed Technological and Clinical Insights

Understanding the technical nuances of Know Labs Inc's offerings requires an appreciation of both the scientific and practical aspects of its technologies. The Bio-RFID system relies on a precise interaction between electromagnetic waves and biological tissues, capturing signatures that are both unique and replicable. Similarly, the ChromaID system applies principles of spectral analysis to differentiate between subtle variations in material composition. Together, these systems exemplify how advanced technology can be harnessed to solve persistent challenges in clinical diagnostics. The integration of these innovations into wearable devices is poised to offer a practical, everyday application that can change how routine health monitoring is conducted.

Rhea-AI Summary
Know Labs, Inc. (KNW) has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit, showcasing significant progress in non-invasive blood glucose monitoring technology. The company's proprietary radiofrequency (RF) dielectric sensor has shown improved accuracy in measuring blood glucose, with recent clinical studies demonstrating stability, repeatability, and accuracy of its non-invasive continuous blood glucose monitor. Know Labs aims for FDA clearance and plans to deploy its wearable CGM in large-scale clinical trials to determine real-world applicability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
-
Rhea-AI Summary
Know Labs, Inc. (KNW) announces positive interim results from its clinical research study on non-invasive blood glucose monitoring in participants with diabetes. The study demonstrates a Mean Absolute Relative Difference (MARD) of 11.1% using the company's proprietary RF sensor, showing promise for future FDA-cleared continuous glucose monitoring devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.52%
Tags
-
Rhea-AI Summary
Know Labs, Inc. (KNW) secures a funding agreement for up to $12 million with Lind Global Fund II LP, enabling accelerated development of non-invasive medical diagnostic technology. The investment will support hardware development, expanded data collection, algorithm development, and intellectual property expansion. The company aims to validate its technology in large-scale clinical trials for a non-invasive continuous glucose monitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
Rhea-AI Summary
Know Labs, Inc. announces the KnowU, a wearable non-invasive continuous glucose monitor, incorporating a proprietary sensor for FDA submission. The device is smaller, lighter, and includes machine learning capabilities, aiming to revolutionize diabetes management. The KnowU supports accelerated data collection for FDA clinical trials, offering a future solution for accessible and accurate diabetes care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
-
Rhea-AI Summary
Know Labs, Inc. (KNW) reported financial results for Q1 FY 2024, showing a 9.8% reduction in net loss, with a net loss of $3.45 million. Earnings Per Share improved by 50% to a loss of $0.04. The company had cash and cash equivalents of $4.82 million as of December 31, 2023. Know Labs aims to raise funds through equity, preferred stock, and convertible debentures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.91%
Tags
-
Rhea-AI Summary
Know Labs, Inc. (KNW) will host a webcast to review business updates and first quarter results for fiscal year 2024 on February 14, 2024. The company is an emerging developer of non-invasive medical diagnostic technology and is focused on developing the first FDA-cleared non-invasive blood glucose monitoring device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
conferences earnings
Rhea-AI Summary
Know Labs, Inc. (KNW) will present updated clinical research results and developments of its non-invasive blood glucose monitor at the International Fair of New Technologies in Diabetes. The company will share updates on the latest developments of its non-invasive blood glucose monitor and present results from its ongoing clinical research, with two abstracts accepted for e-poster presentation in the scientific program. Dr. Virend K. Somers of the Mayo Clinic will present the results from the current clinical research protocol, assessing the accuracy of the Know Labs radiofrequency (RF) sensor for non-invasive blood glucose measurement in participants with prediabetes and Type 2 diabetes using venous blood as comparative reference. Know Labs will also sponsor an invitation-only luncheon hosted by Children With Diabetes (CWD) during the conference to discuss non-invasive glucose monitoring innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
none
-
Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) reported a net loss of $15.29 million dollars in FY2023, compared to a net loss of $20.07 million dollars in FY2022, a reduction in net loss of 23.8%. R&D expenses for FY2023 were $7.73 million dollars, an increase of 43.5% year over year. The company had cash and cash equivalents of $8.02 million dollars, and it expects to raise additional funds through the issuance of equity, preferred stock, and convertible debentures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.33%
Tags
-
Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) appoints four new members to its Medical and Scientific Advisory Board. Jeff Hitchcock, Karmeen Kulkarni, Dr. Meng Tan, and Dr. Satish Garg bring extensive clinical diabetes management and FDA expertise to the board. They will support the development and FDA clearance of the company's non-invasive continuous glucose monitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.76%
Tags
management
Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) will host a webcast to review business updates and results for its fiscal year ended on September 30, 2023, on December 19, 2023, beginning at 1:30 pm PT. The company is an emerging developer of non-invasive medical diagnostic technology and is progressing in developing the first FDA-cleared non-invasive blood glucose monitoring device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
conferences earnings

FAQ

What is the current stock price of Know Labs (KNW)?

The current stock price of Know Labs (KNW) is $0.6999 as of April 1, 2025.

What is the market cap of Know Labs (KNW)?

The market cap of Know Labs (KNW) is approximately 1.8M.

What core technologies power Know Labs Inc's diagnostic solutions?

Know Labs Inc utilizes proprietary Bio-RFID and ChromaID technologies that leverage electromagnetic energy to capture unique bio-signatures for non-invasive diagnostics.

How do Know Labs' technologies improve patient care?

By offering non-invasive solutions, such as wearable devices for blood glucose monitoring, the company minimizes patient discomfort and streamlines diagnostic procedures.

What is the primary business focus of Know Labs Inc?

The company focuses on the development, marketing, and sales of innovative diagnostic devices that deliver accurate and non-invasive testing solutions for healthcare applications.

In which industry does Know Labs Inc operate?

Know Labs Inc operates in the medical diagnostics and healthcare technology sector, specifically targeting advancements in non-invasive testing methods.

How does Know Labs differentiate itself from traditional diagnostic methods?

Its unique approach using electromagnetic energy to record bio-signatures allows for more efficient and patient-friendly diagnostics compared to conventional invasive lab tests.

What potential applications arise from Know Labs' wearable diagnostic technology?

The wearable devices under development aim to measure critical health parameters, like blood glucose, non-invasively, thereby enhancing daily health monitoring and patient compliance.
Know Labs

NYSE:KNW

KNW Rankings

KNW Stock Data

1.80M
2.25M
19.93%
5.52%
2.24%
Scientific & Technical Instruments
Measuring & Controlling Devices, Nec
Link
United States
SEATTLE